OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
Subscribe To Our Newsletter & Stay Updated